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a b s t r a c t
Like most animal viruses, studying inﬂuenza A in model systems requires secondary methodologies to
identify infected cells. To circumvent this requirement, we describe the generation of replication-
competent inﬂuenza A red ﬂuorescent viruses. These inﬂuenza A viruses encode mCherry fused to the
viral non-structural 1 (NS1) protein and display comparable growth kinetics to wild-type viruses in vitro.
Infection of cells with inﬂuenza A mCherry viruses was neutralized with monoclonal antibodies and
inhibited with antivirals to levels similar to wild-type virus. Inﬂuenza A mCherry viruses were also able
to lethally infect mice, and strikingly, dose- and time-dependent kinetics of viral replication were
monitored in whole excised mouse lungs using an in vivo imaging system (IVIS). By eliminating the need
for secondary labeling of infected cells, inﬂuenza A mCherry viruses provide an ideal tool in the ongoing
struggle to better characterize the virus and identify new therapeutics against inﬂuenza A viral
infections.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A virus (IAV), a member of the family Orthomyxovir-
idae, is a human respiratory pathogen that causes annual epi-
demics and occasional pandemics of considerable public health
and economic impact (Molinari et al., 2007). The 20th century was
marred by three documented inﬂuenza A pandemics: the Spanish
ﬂu (H1N1) of 1918, the Asian ﬂu (H2N2) of 1957 and the Hong
Kong ﬂu (H3N2) of 1968, which together resulted in upwards of 60
million deaths (Kilbourne, 2006). The ﬁrst inﬂuenza pandemic of
the 21st century was declared in 2009 after the emergence of a
quadruple-reassortant swine-origin H1N1 IAV that in less than one
year infected more than 600,000 people worldwide (Louie et al.,
2011; Smith et al., 2009). Additionally, the emergence of avian IAV
strains that infect humans sporadically, such as H5N1, H7N9, and
H10N8 have heightened worldwide concerns for pandemic pre-
paredness, and together with the 2009 pandemic H1N1 IAV,
provide credence for the improvement in monitoring, preventing
and treating IAV infections (Ali et al., 2000; Herfst et al., 2012;
Lopez-Martinez et al., 2013; Uyeki and Cox, 2013).
The IAV genome contains eight single-stranded RNA molecules
of negative polarity, which are encapsidated into distinct viral
ribonucleoprotein (vRNP) particles that contain the viral polymer-
ase subunits PB2, PB1 and PA and multiple copies of the viral
nucleoprotein (NP) (Palese, 2007). Genome replication and tran-
scription occurs in the nucleus of infected cells and requires the
tripartite polymerase complex, NP, and viral RNA (vRNA) (Wright
et al., 2007). Reverse genetics, or the ability to rescue recombinant
viruses from plasmid DNA, requires vRNA expression of all eight
genome segments and protein expression of the aforementioned
PB2, PB1, PA and NP (Fodor et al., 1999; Neumann et al., 1999). This
approach has provided an excellent tool to study IAV biology
(Ozawa and Kawaoka, 2011) and to develop a new generation of
IAV vaccines (Martinez-Sobrido and Garcia-Sastre, 2010). Further-
more, modiﬁcation of the IAV genome has resulted in replication-
incompetent (Baker et al., 2013; Martinez-Sobrido et al., 2010) or
-competent viruses that express foreign genes, including several
reporter genes, which are expressed as fusion products to viral
proteins (Avilov et al., 2012; Heaton et al., 2013; Kittel et al., 2004;
Lakdawala et al., 2014; Li et al., 2010; Manicassamy et al., 2010;
Martinez-Sobrido et al., 2010; Ozawa et al., 2011; Pan et al., 2013;
Pena et al., 2013; Rimmelzwaan et al., 2007; Tran et al., 2013). An
IAV protein commonly targeted for such genetic manipulation is
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the non-structural 1 (NS1) protein because of its short length, high
copy number in infected cells, and redundant functions in antag-
onizing innate immunity (Hale et al., 2008; Palese, 2007). The NS1
protein is encoded on a collinear mRNA derived from the smallest
vRNA segment eight, which is alternatively spliced to produce the
nuclear export protein (NEP) mRNA, and is expressed to 10% the
levels of NS1 (Lamb and Lai, 1980; Paterson and Fodor, 2012). Virus
assembly requires NEP, thus genetic modiﬁcations that yield
differences in levels of expression can hinder successful virus
rescue or attenuate the virus (Paterson and Fodor, 2012).
To evaluate viral infection in vitro and ex or in vivo, ﬂuorescent
viruses are advantageous because secondary steps such as immu-
noﬂuorescence staining or addition of bioluminescence substrates
are not required to detect infected cells (Kayali et al., 2008; Kumar
and Henrickson, 2012). A green ﬂuorescent protein (GFP)-expres-
sing IAV has been described (Kittel et al., 2004; Manicassamy et al.,
2010), but its use is limited due to spectral overlap of GFP and
tissue autoﬂuorescence (Vintersten et al., 2004) or when GFP-
expressing animals or cell lines serve as hosts of infection (Miller,
2011). As an alternative reporter, red ﬂuorescent proteins have an
excitation and emission spectra that is more conducive to in vivo
or ex vivo imaging, offering less autoﬂuorescence and deeper
tissue penetrance (Shaner et al., 2005, 2007). Furthermore, labora-
tory evolution of red ﬂuorescent proteins has led to a molecule,
mCherry, that possesses higher quantum yield, a longer half-life,
and that does not aggregate, as opposed to its ancestral protein
derived from Discosoma sp. (Shaner et al., 2005).
Here, we describe for the ﬁrst time the generation of replication-
competent red ﬂuorescent IAVs, where the NS1 protein of A/Puerto
Rico/08/1934 (H1N1; PR8) is fused to mCherry, and the remaining
seven segments are derived from PR8 or A/California_NYICE_E3/04/
2009 (pH1N1). In vitro, mCherry IAVs are neutralized by monoclonal
antibodies or inhibited by antivirals similarly to wild-type (WT)
recombinant viruses, representing an excellent option for the rapid
identiﬁcation of neutralizing antibodies or antivirals using high-
throughput screening. In mice, PR8 mCherry replication can be
directly visualized and quantiﬁed from whole excised lungs using
an in vivo imaging system (IVIS). These results offer a promising
option to directly study the biology of inﬂuenza virus and to
evaluate experimental countermeasures to treat inﬂuenza viral
infections in vitro and ex vivo.
Results
Generation of a recombinant inﬂuenza A PR8 virus expressing the
mCherry ﬂuorescent protein
Generation of replication-competent reporter-expressing IAV
requires that the inserted reporter gene neither impair critical
functions of the protein(s) encoded by the native gene segment to
which it is appended nor disrupt the packaging signals therein.
The NS1 protein has previously been shown to tolerate fusion to
foreign proteins including GFP (Kittel et al., 2004; Manicassamy
et al., 2010; Perez et al., 2013), and thus is an ideal viral protein for
reporter gene conjugation. However, red ﬂuorescent proteins are
preferred for in vivo studies (Shaner et al., 2005, 2007). Because
the NS segment is alternatively spliced to produce NEP, two silent
mutations were introduced in the splice acceptor site to avoid
splicing (Hale et al., 2008; Kochs et al., 2007). To produce NEP, the
porcine teschovirus-1 (PTV-1) 2A autoproteolytic cleavage site was
inserted between NS1 and NEP so that both proteins (NS1 and
NEP) would be translated individually (Fig. 1), like previously
described (Manicassamy et al., 2010). Importantly, the NS1 and
NEP N-terminal overlapping open reading frame was duplicated
downstream of the PTV-1 2A site to assure NEP synthesis
(Paterson and Fodor, 2012). Using two unique BsmBI restriction
sites, mCherry was cloned and fused to NS1 and used to generate a
recombinant PR8 NS1-mCherry virus (hereafter referred to as PR8
mCherry) using plasmid-based reverse genetics (Martinez-Sobrido
and Garcia-Sastre, 2010).
Characterization of PR8 mCherry virus
To evaluate if PR8 encoding NS1 fused to mCherry could be
directly visualized in vitro and to evaluate the subcellular localiza-
tion of NS1 during PR8 WT and mCherry infection, ﬂuorescence
(mCherry) and indirect immunoﬂuorescence microscopy were
used (Fig. 2A and B). As expected, only cells infected with PR8
mCherry were ﬂuorescent upon examination with a red ﬁlter. In
cells infected with PR8 mCherry, the nuclear localization of NP
(Fig. 2A) was similar to that of PR8 WT. Importantly, NS1 was
similarly distributed in PR8 WT and mCherry infected cells
(Fig. 2B).
PR8 WT and mCherry virus identity was then conﬁrmed by
RT-PCR and Western blotting (Fig. 2C and D). Expected band sizes
of approximately 890 and 1891 nucleotides were ampliﬁed and
resolved, corresponding to the NS vRNA from PR8 WT or mCherry,
respectively (Fig. 2C). Additionally, primers amplifying the NS1-
mCherry fusion only ampliﬁed an accurately sized band (1433 nt)
from PR8 mCherry infected cells. As expected, NP mRNA levels
were detected similarly from both PR8 WT and mCherry infected
cells. We next evaluated protein expression by Western blotting
using antibodies speciﬁc for NS1, mCherry, or NP as a control of
viral infection (Fig. 2D). The amount of NS1 was slightly decreased
in cells infected with PR8 mCherry as compared with PR8 WT,
although NS1-mCherry was easily detected using the mCherry
PAb. Differences between NS1 and NS1-mCherry signal intensities
observed with the 1A7 monoclonal antibody correlate with a
lower level of NP in PR8 mCherry infection, but may additionally
be due to lower afﬁnity of 1A7 when NS1 is fused to mCherry
(Fig. 2D).
Growth properties of PR8 mCherry
Virus ﬁtness in cell culture was next assessed by examining the
multicycle growth properties and plaque formation of PR8
mCherry, as compared to PR8 WT (Fig. 3). PR8 mCherry viral
kinetics were similar, albeit the total virus yield was lower after
24 h, with respect to PR8 WT (Fig. 3A). When evaluating the
plaque phenotype, only PR8 mCherry formed ﬂuorescent plaques
(Fig. 3B), but in agreement with virus kinetics, the plaque size was
slightly reduced compared to PR8 WT by immunostaining with an
anti-NP monoclonal antibody (Fig. 3C). Importantly, all plaques
detected using the anti-NP monoclonal antibody expressed
mCherry (white arrows), indicating that all infectious viruses
express mCherry.
Ability of NS1-mCherry fusion protein to inhibit IFNβ promoter
activation
NS1 is a multifunctional protein that uses multiple mechanisms
to counteract the type I interferon (IFN) response during viral
infection (Hale et al., 2008). In order to evaluate if NS1-mCherry
retained the ability to antagonize IFNβ activation, MDCK cells
expressing GFP and FFluc under the control of the IFNβ promoter
(Hai et al., 2008) were infected with PR8 WT and mCherry viruses
(Fig. 4). As an internal control, cells were similarly infected with
PR8 ΔNS1 (Garcia-Sastre et al., 1998), which potently induces IFNβ
promoter activation (Geiss et al., 2002). GFP expression in infected
cells indicated that PR8 mCherry infection inhibited IFNβ promo-
ter activation to levels comparable to PR8 WT and, as expected,
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Fig. 1. Schematic representation of the modiﬁed IAV PR8 NS segments. IAV PR8 NS segment viral products are indicated by white (NS1) or gray (NEP) boxes. NCR denotes
non-coding regions. Nucleotide length for the modiﬁed IAV PR8 NS segment is indicated. Sequences of mCherry and (PTV-1) 2A are indicated in red and blue boxes,
respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Characterization of PR8 mCherry virus. MDCK cells were mock infected (-), or infected with PR8 WT or PR8 mCherry viruses. (A and B) Analysis of protein expression
by ﬂuorescence and immunoﬂuorescence: At 18 h post-infection (MOI 0.1), cells were ﬁxed, visualized for mCherry expression, and stained for PR8 NP (A) or NS1 (B). DAPI
was used for nuclear staining. Representative images (20 magniﬁcation) from three independent experiments are included. Scale bar, 100 mm. (C and D) Analysis of RNA
and protein expression: At 18 h post-infection (MOI 1), RNA (C) and protein expression (D) were examined. cDNA synthesis for NS or NP vRNA was performed using IAV NS
and NP vRNA speciﬁc primers. cDNA synthesis of mRNA was performed using oligo dT. Speciﬁc primers for PCR were used to amplify NS and NP vRNAs and mRNA for
mCherry and cellular GAPDH as internal controls. Protein expression levels for NS1, NP and mCherry were evaluated using protein speciﬁc antibodies. Actin was used as a
loading control. Numbers indicate the size of molecular markers in nucleotides (C) or kDa (D) for DNA and protein products, respectively.
A. Nogales et al. / Virology 476 (2015) 206–216208
PR8 ΔNS1 failed to inhibit IFNβ promoter activation (Fig. 4A).
Similar results were obtained by analyzing luciferase expression
from infected cell extracts (Fig. 4B).
Use of IAV expressing mCherry for the identiﬁcation of antivirals and
neutralizing antibodies
Identiﬁcation of compounds that inhibit IAV generally require
the use of secondary visualization approaches to evaluate viral
infection (Beyleveld et al., 2013). An alternative approach for the
identiﬁcation of IAV antivirals, compatible with high-throughput
screening, is urgently needed to identify new antivirals that
overcome virus resistance. To demonstrate that IAV expressing
mCherry is a valid surrogate to identify antivirals, we examined
the ability of A3 (Hoffmann et al., 2011) and ribavirin (Cheung
et al., 2014) to inhibit mCherry virus expression (Fig. 5A and B). A3
is a small molecule inhibitor of de novo pyrimidine biosynthesis
that has been shown to inhibit IAV infection in vitro (Hoffmann et
al., 2011), however, the compound has yet to be tested against the
pH1N1 strain. Therefore, we ﬁrst sought to rescue a recombinant
pH1N1 virus containing the NS1-mCherry from PR8 (pH1N1
mCherry), using similar reverse genetics approaches to those
described for rescuing PR8 mCherry, and to evaluate the inhibitory
capacity of A3 against PR8 and pH1N1 mCherry viruses. Efﬁcient
virus rescue ﬁrst indicated that the PR8 NS mCherry construct
could be used in another H1N1 virus backbone. At high concen-
trations of ribavirin or A3 (starting concentration of 100 or 20 mM,
respectively), PR8 mCherry was inhibited in a dose-dependent
manner, as determined by mCherry expression via ﬂuorescence
microscopy (data not shown) or a plate reader (Fig. 5A). Similarly,
pH1N1 mCherry was also inhibited (Fig. 5B), but the pandemic
strain was less sensitive to A3 as compared to PR8 (Table 1).
Fig. 3. Growth kinetics and plaque morphology of PR8 WT and mCherry viruses. (A) Multicycle growth kinetics. Virus titers from tissue culture supernatants of PR8 WT and
mCherry infected (MOI 0.001) MDCK cells at the indicated times post-infection were analyzed by immunofocus assay (FFU/ml). Data represent the means7SD of triplicates.
Dotted line denotes the limit of detection (200 FFU/ml). nPo0.05 using an unpaired two-tailed Student’s t test (n¼3 per time point). (B and C) Plaque phenotype. Plaque
sizes of PR8 WT and mCherry viruses in MDCK cells were evaluated 3 days post-infection by ﬂuorescence (B) and immunostaining (C) using the HT103 NP monoclonal
antibody. White arrows indicate correlation between mCherry ﬂuorescent and NP positive plaques with the PR8 mCherry.
Fig. 4. Analysis of IFNβ promoter activation by PR8 mCherry virus: MDCK pIFNβ-GFP/IFNβ-FFluc cells were infected (MOI 2) with PR8 WT, mCherry, or ΔNS1 viruses and
analyzed for IFNβ promoter activation 10 h post-infection. (A) IFNβ promoter activation by GFP expression: Activation of IFNβ promoter (GFP) and infection with PR8
mCherry was visualized directly with a ﬂuorescence microscope. Infection of PR8 WT and ΔNS1 PR8 viruses was visualized by NP immunostaining using the HT103 MAb.
Representative ﬁelds (20 magniﬁcation) are shown. Scale bar, 100 mm. (B) IFNβ promoter activation by luciferase expression: Extracts from cells infected as in panel A were
evaluated for IFNβ promoter activation by FFluc expression. Data show means7SD of the results from triplicate samples. The induction of IFNβ was represented as fold
induction relative to values from mock-infected cells. nPo0.05 using an unpaired two-tailed Student’s t test (n¼3 per time point).
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To validate the sensitivity of the mCherry viruses to these
antivirals, recombinant PR8 and pH1N1 WT and mCherry viruses
were tested in antiviral assays that measure virus output (Bauman
et al., 2013). Virus release into tissue culture supernatants were
determined by immunofocus assay (ﬂuorescent focus units, FFU),
using an NP monoclonal antibody. All virus titers were determined
across the same dilution series, and IC50 values calculated using a
sigmoidal dose–response curve (Table 2). Regardless of the drug or
IAV strain used, WT and mCherry IC50 values were similar, within
1–2 dilution values, and consistent with those in the literature
(Hoffmann et al., 2011; Nguyen et al., 2009, 2010). Interestingly,
both ﬂuorescence and classic approaches indicate that pH1N1 is
more resistant to A3 compared to PR8.
Similar to antiviral evaluation, virus neutralization assays to
determine antibody-mediated virus inhibition require the use of
secondary approaches to detect the presence of the virus, such as
cell staining, immunoﬂuorescence assay, ELISA or hemagglutination
assays (Bauman et al., 2013; Webster and Stoehr, 2002). To over-
come this additional step, PR8 and pH1N1 mCherry viruses were
used to evaluate the neutralizing activity of monoclonal antibodies
speciﬁc for PR8 (PY102) (Dinca et al., 1993), pH1N1 (31C2) (Medina
et al., 2010) or both PR8 and pH1N1 (pan-H1 stalk-reactive mono-
clonal antibody 6F12) (Tan et al., 2012) by ﬂuorescence expression
using ﬂuorescence microscopy (data not shown) or a ﬂuorescence
plate reader (Fig. 5C and D). PR8 mCherry was speciﬁcally neutra-
lized by PY102 but not 31C2 monoclonal antibodies (Fig. 5C),
whereas pH1N1 was neutralized by 31C2 but not PY102 (Fig. 5D).
Both mCherry IAVs were neutralized by the pan-H1 6F12 mono-
clonal antibody. Additionally, we used a conventional virus neutra-
lization assays to evaluate if, relative to WT IAVs, mCherry IAVs were
comparably inhibited (Tables 3 and 4). The results show that speciﬁc
neutralization was observed in a manner similar to the ﬂuorescence
approach and to previous reports (Baker et al., 2013; Dinca et al.,
1993; Medina et al., 2010; Tan et al., 2012). These data demonstrate
that mCherry IAVs can be used to evaluate both head- and stalk-
reactive neutralizing antibodies using a ﬂuorescence-based micro-
neutralization assay. Altogether, these studies demonstrate that
mCherry IAVs can be used to identify novel antivirals or neutralizing
Fig. 5. A ﬂuorescence-based assay for the identiﬁcation of IAV antivirals (A and B) and neutralizing antibodies (C and D). Antivirals: MDCK cells were infected (MOI 0.005)
with PR8 (A) or pH1N1 (B) mCherry viruses and incubated with serial dilutions of ribavirin (starting concentration 100 mM, 2-fold dilutions) or A3 (starting concentration
20 mM, 3-fold dilutions) for 24–36 h. As a control, infected cells were not treated. Sigmoidal dose response curves for PR8 (A) or pH1N1 (B) mCherry expression were
evaluated using a ﬂuorescence microplate reader. Percent inhibition was normalized to infection in the absence of drug. Data show means7SD of the results determined for
triplicates. Neutralizing antibodies: MDCK cells were infected (MOI 0.005, 24–36 h) with PR8 (C) or pH1N1 (D) mCherry viruses that were pre-incubated with 2-fold serial
dilutions of HA speciﬁc monoclonal antibodies PY102 (PR8, starting concentration, 500 ng/ml), 31C2 (pH1N1, starting concentration, 200 ng/ml) and 6F12 (pan-H1, starting
concentration, 200 mg/ml). Viruses in the absence of antibodies were used as internal control. Sigmoidal dose response curves for PR8 (C) or pH1N1 (D) mCherry expression
were evaluated using a ﬂuorescence microplate reader. Percent neutralization was normalized to infection in the absence of antibody. Note that monoclonal antibodies
PY102 and 31C2 concentrations are in ng/ml log10 scale, while monoclonal antibody 6F12 concentration is in mg/ml log10 scale. Data show means7SD of the results
determined for triplicates.
Table 1
IC50 of compounds by ﬂuorescence-based assay.
IC50a
Virus Ribavirin A3
PR8 mCherry 6.944 0.3956
pH1N1 mCherry 3.476 0.9556
a Compound concentration (mM) determined by serial-titration of drug with
triplicate infections.
Table 2
IC50 of compounds by FFU titration method.
IC50a
Virus Ribavirin A3
PR8 WT 3.994 0.4828
PR8 mCherry 1.41 1.08
pH1N1 WT 13.98 8.735
pH1N1 mCherry 3.938 11.14
a Compound concentration (mM) determined by serial-titration of drug with
triplicate infections.
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antibodies without the use of secondary methodologies to deter-
mine viral infection and are therefore more compatible with high-
throughput screening.
PR8 mCherry virus infection in mice
Next, we evaluated if PR8 mCherry was pathogenic in mice as a
surrogate for virus replication. If PR8 mCherry replicates within
inoculated mouse lungs, mCherry expression could potentially be
used for virus detection and/or quantiﬁcation. To that end, we ﬁrst
assessed the mouse lethal dose 50 (MLD50) of PR8 mCherry by
intranasally (i.n.) inoculating mice (n¼6) with 102, 103, 104 or
105 FFU of PR8 mCherry and monitored body weight loss and
mortality daily for two weeks (Fig. 6). All mice inoculated with
105 or 104 FFU succumbed to viral infection, whereas four out of
6 mice inoculated with 103 FFU survived. All mice inoculated with
102 FFU survived viral infection (Figs. 6A and B). Using the method
of Reed and Muench (Reed, 1938), the MLD50 of PR8 mCherry is
1.8103 FFU, which although not directly compared here, is 50–
100 times higher than PR8 WT (10–50 FFU, tested in age/sex/breed-
matched mice) (Nogales et al., 2014). Thus PR8 mCherry can lead to
a lethal infection in mice, likely caused by virus replication in vivo.
Kinetics of PR8 mCherry protein expression in mouse lungs
To evaluate mCherry ﬂuorescence ex vivo, lungs from mice
inoculated with 102, 103, 104 or 105 FFU of PR8 WT or mCherry
were surgically removed three days post-infection, and ﬂuores-
cence was quantiﬁed with an IVIS Spectrum multispectral imaging
instrument (Fig. 7A). When mean radiant efﬁciency was deter-
mined for regions of interest corresponding to lung explants
(n¼3), a dose-dependent ﬂuorescence intensity increase was
detected in PR8 mCherry-infected mice that peaked with a dose
of 104 FFU (Fig. 7B) at this time point. Viral infection was also
quantiﬁed by determining viral titers (Fig. 7C). As expected,
presence of PR8 mCherry in mice lungs was proportional to and
greater than the amount of virus used for mice inoculations, and
corroborated the MLD50 observations, that PR8 mCherry can
replicate within lung tissue.
Lastly, the time-dependent kinetics of PR8 mCherry replication
and ﬂuorescence expression were evaluated in mouse lungs
(Fig. 8). To that end, mice (n¼3) were i.n. inoculated with
105 FFU of PR8 mCherry and evaluated for ﬂuorescence expression
and viral titers at days 2, 4 and 6 post-infection. Due to the lack of
ﬂuorescence expression in PR8 WT inoculated mice (Fig. 7), PBS
inoculated mice were further used as controls. In agreement with
Fig. 7, mCherry expression was easily observed over background
(PBS-inoculated naïve animals, Fig. 8A) at all days post-infection
and peaked at day 4 post-infection. This was conﬁrmed when
mean radiant efﬁciency was calculated (Fig. 8B). Importantly, these
results correlated with viral titers in lungs from infected animals
(Fig. 8C). All together, these ﬁndings indicate that PR8 mCherry
virus can be used to evaluate viral infection in mice lungs, and that
in mice, the kinetics of PR8 mCherry virus infection are similar to
that of recombinant PR8 WT virus infection (Nogales et al., 2014).
Discussion
Providing the ability to monitor viral infection in real time is
advantageous to study the biology of IAV, to evaluate the effec-
tiveness of current or potential antivirals, and to test the effec-
tiveness of vaccine approaches. Here we describe the generation
and characterization of replication-competent inﬂuenza A/Puerto
Rico/8/34 (PR8) and A/California/04/09 (pH1N1) viruses expres-
sing a red ﬂuorescent mCherry protein as valid surrogates to
facilitate the study of these viruses in vitro and ex vivo.
Both mCherry IAVs contain a recombinant PR8 NS segment
that expresses the viral NS1 protein fused to mCherry. Co-linear
NEP expression is maintained by shifting the entire NEP ORF
downstream of the PTV-1 2A cleavage site (Fig. 1). IAV infection
can be visualized in real time without the use of secondary
antibodies or enzymes and vRNA and protein composition
Table 3
NT50 of MAbs by ﬂuorescence-based assay.
NT50a
Virus PY102 (ng/ml) 31C2 (ng/ml) 6F12 (mg/ml)
PR8 mCherry 12.95 N/A 338.7
pH1N1 mCherry N/A 3.152 231.5
a MAb concentration determined by serial-titration of Ab with triplicate
infections. N/A, not applicable.
Table 4
NT50 of MAbs by VN assay.
NT50a (SD)
Virus PY102 (ng/ml) 31C2 (ng/ml) 6F12 (mg/ml)
PR8 WT 44 (22) 4200 (0) 4200 (0)
PR8 mCherry 44 (22) 4200 (0) 4200 (0)
pH1N1 WT 4500 (0) 140 (71) 4200 (0)
pH1N1 mCherry 4500 (0) 100 (110) 4200 (0)
a MAb concentration determined by serial-titration of Ab with triplicate
infections.
Fig. 6. Virulence of PR8 mCherry in mice: Female 6-to-8-week-old C57BL/6 mice
(n¼6) were i.n. inoculated with 102, 103, 104 or 105 FFU of PR8 mCherry and
monitored daily for 2 weeks for body weight loss (A) and survival (B). Mice that lost
25% or greater of their initial body weight were sacriﬁced. The MLD50 for PR8
mCherry was determined by the method of Reed and Muench (Reed, 1938). Data
represent means7SEM of the results determined for individual mice.
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demonstrate insertion of mCherry (Fig. 2). As compared to PR8
WT, PR8 mCherry has similar, but slightly reduced replication
kinetics and plaque size phenotype (Fig. 3), but maintains the
ability to inhibit IFNβ promoter activation during viral infection
(Fig. 4).
The only class of antivirals currently FDA-approved against
circulating strains of IAV are neuraminidase (NA) inhibitors, and
recent meta-analyses of clinical data suggests that treatment,
although beneﬁcial, does not decrease serious IAV complications
(Jefferson et al., 2014). Thus, a rapid and sensitive assay to screen
for anti-IAV compounds is urgently needed. Both PR8 and pH1N1
mCherry viruses were susceptible to dose-dependent inhibition by
A3 and ribavirin (Fig. 5), yielding similar results as those obtained
with PR8 and pH1N1 WT viruses (Tables 1 and 2). Moreover, the
effectiveness of A3 against currently circulating pH1N1, pending
its toxicity proﬁle in humans, is a promising addition to the
current anti-inﬂuenza treatment regime. The observation that
pH1N1 was less susceptible to A3 than PR8 suggests differences
in infected cell metabolism or polymerase substrate afﬁnity. These
results demonstrate the potential use of mCherry IAVs for high-
throughput screening to identify novel antivirals without limita-
tions associated with more laborious titration assays that are
needed to quantitate WT virus.
Knowing that inhibition of IAV-driven mCherry expression corre-
lated with a reduction in virus titer, we tested if mCherry IAV could be
used to detect neutralizing antibodies via a ﬂuorescence-based micro-
neutralization assay and a ﬂuorescencemicroplate reader (Fig. 5). Using
well-characterized IAV monoclonal antibodies, our results demonstrate
the feasibility to detect inﬂuenza strain-speciﬁc or broadly neutralizing
antibodies using this approach. Importantly, similar neutralization titers
were obtained with classic virus neutralization assays using recombi-
nant PR8 and pH1N1WT viruses (Tables 3 and 4). Without the need of
secondary assays for viral quantiﬁcation, large collections of hybrido-
mas could potentially be evaluated, thereby simplifying their detection
using high-throughput screening approaches.
Both ours and others’ observations documented the attenuation of
reporter-expressing IAV as compared to the recombinant WT virus
(Fig. 6). For PR8 mCherry, high MLD50 values may be caused by altered
levels of NS1 and/or NEP expression, which are known to affect viral
replication both in vitro and in vivo (Bullido et al., 2001; Paterson and
Fodor, 2012). Although the antagonism of innate immunity in vivowas
not tested here, our in vitro results suggest that the anti-IFN function of
NS1-mCherry is largely maintained. Importantly, both, the neutralizing
activity of monoclonal antibodies or the antiviral activity of small
molecule compounds could be evaluated in mice by directly evaluat-
ing mCherry expression from lungs of inoculated mice ex vivo since
expression of mCherry in the excised whole lungs correlated with the
amount of virus (Figs. 7 and 8).
Our strategy to express mCherry fused to IAV NS1 is similar to a
NS1-GFP fusion recently described (Manicassamy et al., 2010).
However, IAV NS1-mCherry seems to be more stable than IAV
NS1-GFP since we have not observed NS1-mCherry viruses that
lack expression of the ﬂuorescent reporter. Nevertheless, the
stability of NS1-mCherry and NS1-GFP viruses was not directly
Fig. 7. Dose escalation and quantiﬁcation of PR8 mCherry viral lung infection: Female 6-to-8-week-old C57BL/6 mice (n¼3) were i.n. inoculated with 102, 103, 104 or 105 FFU
of PR8 WT or mCherry viruses. Three days post-infection, lungs were harvested and ﬂuorescence (A and B) and viral replication (C) were determined. A and B) Fluorescence
imaging of whole lungs using IVIS: Representative ﬂuorescence images with radiant efﬁciency heat maps overlaid (A) and mean values of regions of interest (B) were
normalized to PR8 WT-infected mice at each dose, and induction of ﬂuorescence determined. Columns represent mean7SD. Statistical signiﬁcance was calculated by using
two-way ANOVAwith Bonferonni post test; ***indicates P values o0.001. (C) Viral lung titers: PR8 WT and mCherry replication in mice lungs were assessed by immunofocus
assay (FFU/ml). Bars represent the mean7SD of lung virus titers. Statistical analysis was conducted using the Student’s t test. nPo0.05 (n¼3). Dotted line denotes the limit
of detection (200 FFU/ml).
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compared. Moreover, NS1-GFP virus cannot be used in in vitro and/
or in ex vivo systems engineered to express GFP. Furthermore, red
ﬂuorescent proteins are better suited for ex vivo imaging due to
natural green autoﬂuorescence produced in tissue (Shaner et al.,
2005, 2007).
Recombinant viruses expressing luciferase genes have also been
reported (Heaton et al., 2013; Tran et al., 2013). Heaton et al. (2013)
developed a replication-competent luciferase IAV by inserting the
Gaussia luciferase (GLuc) reporter gene into the C-terminus of the
PB2. PB2 and GLuc ORFs were separated with a 2A protease cleavage
site, which cleaves the two proteins co-translationally. Similarly, Tran
et al. (2013) engineered a replication-competent IAV reporter virus,
suitable for in vivo imaging, that expressed NanoLuc luciferase
separated with a 2A site of the viral PA gene. Although we have not
yet detected IAV-driven mCherry expression in living mice, perhaps
due to ﬂuorescence intensity, an advantage of using ﬂuorescent
proteins instead of luciferases is that it is not necessary to inject
luciferase substrates into the inoculated mice, as the amount of
bioluminescent signal produced by luciferase depends on the efﬁ-
ciency of substrate delivery, which can be anatomically restrictive.
Furthermore, because of the signal intensity and its retention within
infected cells, mCherry is an ideal methodology to identify individu-
ally infected cells by intravital multiphoton imaging (Burrell et al.,
2013; Gonzalez et al., 2010; Murooka and Mempel, 2013). Lastly,
analysis of cells infected with ﬂuorescent protein-expressing IAV is
more rapid in vitro. With decreases in the analysis speed and cost, IAV
mCherry opens the door for future studies to better understand the
biology of inﬂuenza viruses as well as for high-throughput screening
of both antivirals and neutralizing antibodies in vitro and ex vivo.
Materials and methods
Cell lines
MDCK and 293T cells were grown at 37 1C with 5% CO2, in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), and 1% PSG (penicillin, 100 units/ml;
streptomycin 100 mg/ml; L-glutamine, 2 mM) (Nogales et al., 2014).
MDCK cells expressing GFP and ﬁreﬂy luciferase (FFluc) genes
under the control of the interferon (IFN) β promoter (MDCK
pIFNβ-GFP/IFNβ-FFluc) were previously described (Hai et al.,
2008).
Generation of the NS rescue plasmid containing NS1-mCherry fusion
To engineer a PR8 NS segment where the C-terminal of NS1 is
fused to a gene of interest, we employed overlapping PCR and
standard molecular biology techniques to introduce two BsmBI sites
into an ambisense pDZ rescue plasmid (Schickli et al., 2001). This
new plasmid, named pDZ-NS-2xBsmBI, contains the NS1 open
reading frame (ORF), without the stop codon or splice acceptor site,
Fig. 8. Kinetics of PR8 mCherry infection in mouse lungs: Female 6-to-8-week-old C57BL/6 mice (n¼3) were i.n. inoculated with PBS (naïve) or with 105 FFU of PR8 mCherry.
At days 2, 4, and 6 post-infection (dpi), mice lungs were harvested for ﬂuorescence (A and B) and production of infectious virus (C). (A and B) Fluorescence imaging of
infected lungs: Lungs from mock-infected (naïve) and PR8 mCherry infected mice were harvested and analyzed by IVIS. (A) Representative ﬂuorescence images with radiant
efﬁciency heat maps overlaid. (B) Mean values of regions of interest were normalized to naïve mice at each time point, and induction of ﬂuorescence was determined.
Columns represent mean7SD. Statistical signiﬁcance was calculated using two-way ANOVA with Bonferonni post test; nnnindicates P valueso0.001; nnPo0.01; nPo0.05.
(C) Viral lung titers: To evaluate virus replication, whole lungs were homogenized, and used to quantify viral titers by immunofocus assay (FFU/ml). Bars represent the
mean7SD of lung virus titers. Dotted line denotes the limit of detection (200 FFU/ml).
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and two BsmBI sites followed by the porcine teschovirus-1 (PTV-1)
2A autoproteolytic cleavage site (ATNFSLLKQAGDVEENPGP) and NEP.
The mCherry gene was then subcloned from a pCAGGS mCherry
plasmid using oligonucleotides designed to introduce complemen-
tary BsmBI sites to generate the pDZ-NS-mCherry plasmid for viral
rescues. Plasmid constructs were conﬁrmed by sequencing (ACGT,
Inc.). PR8 pDZ-NS-mCherry plasmid was used for the generation of
PR8 and pH1N1 mCherry-expressing viruses.
Rescue of recombinant mCherry IAVs and viral kinetics
Recombinant WT and mCherry IAVs with the genetic backbone
of PR8 (Baker et al., 2014; Nogales et al., 2014; Schickli et al., 2001)
or pH1N1 (Baker et al., 2013; Medina et al., 2010) were rescued
using previously described ambisense reverse genetics approaches
(Fodor et al., 1999; Hoffmann et al., 2000; Martinez-Sobrido and
Garcia-Sastre, 2010; Schickli et al., 2001). The viruses were plaque
puriﬁed and ampliﬁed on MDCK cells to generate the viral stock
used in this work. Multicycle virus growth kinetics were per-
formed in MDCK cells (12-well plate format, 5105 cells, tripli-
cates) infected at low multiplicity of infection (MOI) of 0.001 as
previously described (Baker et al., 2014; Bauman et al., 2013;
Nogales et al., 2014). Mean value and standard deviation (SD) were
calculated using Microsoft Excel software.
Protein gel electrophoresis and Western blot analysis
Cell extracts from either mock or virus-infected (MOI 1) MDCK
cells (6-well plate format, 106 cells/well) at 18 h post-infection
were lysed in passive lysis buffer (Promega) and analyzed for
protein expression as previously described (Nogales et al., 2014)
with the indicated primary monoclonal (MAb) or polyclonal (PAb)
antibodies against mCherry (rabbit PAb Raybiotech), NS1 (mouse
MAb 1A7) (Steidle et al., 2010), NP (mouse MAb HT103) (O’Neill
et al., 1998) or actin (mouse MAb Sigma). Bound primary anti-
bodies were detected with anti-mouse or anti-rabbit horseradish
peroxidase (HRP)-conjugated secondary antibodies (1:2000 dilu-
tion, GE Healthcare). Protein bands were detected by chemilumi-
nescence (Hyglo; Dennville Scientiﬁc Inc.).
RT-PCR
Mock and virus-infected (MOI 1) MDCK cells (6-well plate
format, 106 cells/well) were harvested at 18 h post-infection and
total RNA was puriﬁed using Trizol reagent (Invitrogen). cDNAs
were synthesized using SuperScripts II Reverse Transcriptase
(Invitrogen), using 0.5 mg of total RNA as template and an oligo-
dT primer (to amplify total mRNAs) or speciﬁc primers for the NS
and NP vRNAs. The cDNAs were used as templates for semi-
quantitative PCR with primers speciﬁc for the NS and the NP
vRNAs and for the NS1-mCherry and canine GAPDH mRNAs.
Primers available upon request.
Plaque assays and viral titrations
Conﬂuent MDCK cell monolayers (6-well plate format, 106
cells/well) were infected with 10-fold serial dilutions of PR8 WT
or PR8 mCherry viruses. After infection, monolayers were overlaid
with agar and incubated for 3 days at 37 1C. Cells were ﬁxed with
4% paraformaldehyde (PFA), and the overlays were carefully
removed. For visualization of mCherry, PBS was added and plates
were imaged with a Kodak image station (4000 MM Pro molecular
imaging system; Carestream Health, Inc., NY) (Rodrigo et al., 2011)
and Kodak molecular imaging software (v5.0.1.30). Fixed cells
were then permeabilized (0.5% Triton X-100 in PBS for 15 min at
room temperature) and prepared for immunostaining as
previously described (Baker et al., 2014) using the anti-NP MAb
(HT103) and vector kits (Vectastain ABC kit and DAB HRP Substrate
Kit: Vector), according to manufacturer’s speciﬁcations. Where
indicated, viral titers for both WT and mCherry viruses were
determined by using speciﬁc MAbs for NP (HT103) (O’Neill et al.,
1998) as previously described (FFU/ml) (Nogales et al., 2014).
Fluorescence and indirect immunoﬂuorescence assays
MDCK cells were seeded on coverslips and mock-infected or
infected (MOI 0.1) with PR8 WT or PR8 mCherry viruses. At 18 h
post-infection, cells were ﬁxed, permeabilized, and blocked with
PBS/2.5% BSA. After blocking, speciﬁc MAbs for NP (HT103) (O’Neill
et al., 1998) or NS1 (1A7) (Steidle et al., 2010) were diluted in
blocking solution (1 μg/ml) and used to separately detect protein
expression using a FITC-conjugated rabbit anti-mouse polyclonal
secondary antibody (Dako, 1:200). Coverslips were mounted on
glass slides with Prolong Gold (Invitrogen) containing 40,60-diami-
dino-2-phenylindole (DAPI, Research Organics). Images were cap-
tured using a ﬂuorescence microscope (Nikon Eclipse TE2000),
and processed using Adobe Photoshop CS4 (v11.0) software.
Cell-based type I interferon (IFN) assay
To evaluate the levels of IFN produced by infected cells, conﬂuent
monolayers of MDCK pIFNβ-GFP/IFNβ-FFluc cells (12-well plate
format, 5105 cells, triplicates) (Hai et al., 2008, Quinlivan et al.,
2005) were infected (MOI 2) for 10 h with PR8 WT, PR8 ΔNS1
(Garcia-Sastre et al., 1998), or PR8 mCherry viruses. Infection levels
were evaluated by mCherry or NP expression using ﬂuorescence or
immunoﬂuorescence (NP MAb, HT103) as described above. Mean
values and SDs were calculated using Microsoft Excel software. IFNβ
promoter activation was represented as fold change relative to
mock-infected cells.
Virus neutralization and ﬂuorescence-based microneutralization
assays
Virus neutralization assays were performed with PR8 and
pH1N1 WT and mCherry viruses as previously described (Baker
et al., 2014; Steel et al., 2009; Guo et al., 2011). Fluorescence-based
microneutralization assays were performed with PR8 and pH1N1
mCherry viruses using a ﬂuorescence plate reader (DTX-880,
Becton Dickenson) (Martinez-Sobrido et al., 2010). Fluorescence
values of mCherry virus infected cells in the absence of antibody
were used to calculate 100% viral infection. Percent neutralization
was calculated using the following equation: ([ﬂuorescence value
of indicated sera dilution100% infection]/100% infection) (1 0 0)
(Rodrigo et al., 2011). Triplicate wells were used to calculate the
mean and SD of neutralization, and inhibitory concentration 50
(IC50) was determined by a sigmoidal dose response curve
(Graphpad Prism, v4.0).
Antiviral assays
Antiviral-mediated inhibition of PR8 and pH1N1 WT and
mCherry viruses was evaluated as previously described (Bauman
et al., 2013) using 2- and 3-fold serial dilutions of ribavirin (Sidwell
et al., 1972) or A3 (Hoffmann et al., 2011; Ortiz-Riano et al., 2014)
at a starting concentration of 100 mM and 20 mM, respectively.
Sigmoidal dose-response curves were generated (Graphpad Prism)
to calculate IC50 values.
A. Nogales et al. / Virology 476 (2015) 206–216214
Mouse studies
Female 6-to-8-week-old C57BL/6 mice were purchased from the
National Cancer Institute (NCI) and maintained in the animal care
facility at the University of Rochester under speciﬁc pathogen-free
conditions. Viral infections were performed as previously described
(Nogales et al., 2014). Morbidity was monitored daily by body
weight loss relative to starting weight. Mice showing more than
25% body weight loss were euthanized humanely. To evaluate viral
replication, three mice per group were sacriﬁced at days 3 and 6
post-infection and lungs were removed and homogenized to calcu-
late virus titers using an immunofocus assay (FFU/ml) as indicated
above. Geometric mean titer (GMT) and statistical analysis (Mann–
Whitney test) were performed using GraphPad Prism software
(Nogales et al., 2014). The mouse lethal dose 50 (MLD50) was
determined by inoculating four groups of mice (n¼6) with 10-fold
serial dilutions of virus (105, 104, 103, and 102 FFU) and calculated
using the method of Reed and Muench (Reed, 1938). Expression of
mCherry in whole excised lungs was analyzed using an IVIS
Spectrum multispectral imaging instrument (Caliper Life Sciences,
Inc). Lungs were surgically extracted, washed with PBS, and images
were acquired and analyzed with the Living Image 3.0 software to
determine radiant efﬁciency of regions of interest [p/s/cm2/sr] /
[mW/cm2]. Induction of ﬂuorescence signal was normalized to
WT- or mock-infected naïve animals. Statistical analysis (two-way
ANOVA, bonferonni post-test) was performed using GraphPad Prism
software (v4.0).
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